DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer

Vaccine

Volumn 31, Issue 37, 2013, Pages 3843-3848

  Eriksson, Fredrik ^a   Tötterman, Thomas ^a   Maltais, Anna Karin ^b,c   Pisa, Pavel ^b,f   Yachnin, Jeffrey ^d,e,g  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Cyto Pulse Sciences Inc   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f Roche Glycart AG   (Switzerland)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Electroporation; Intradermal delivery; Prostate cancer; Vaccine

Indexed keywords

CANCER VACCINE; DNA VACCINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; ELECTROPORATION; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

CANCER; ELECTROPORATION; INTRADERMAL DELIVERY; PROSTATE CANCER; VACCINE;

AGED; ANIMALS; ELECTROPORATION; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; MACACA MULATTA; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA;

EID: 84881555063     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.063     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2012.
2. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004, 91:688-694.
3. Prud'homme G.J. DNA vaccination against tumors. J Gene Med 2005, 7:3-17.
4. Gauthier E.R., Chapdelaine P., Tremblay R.R., Dube J.Y. Characterization of rhesus monkey prostate specific antigen cDNA. Biochim Biophys Acta 1993, 1174:207-210.
5. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G., et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002, 20:3399-3408.
6. Low L., Mander A., McCann K., Dearnaley D., Tjelle T., Mathiesen I., et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20:1269-1278.
7. Roos A.K., Eriksson F., Timmons J.A., Gerhardt J., Nyman U., Gudmundsdotter L., et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 2009, 4:e7226.
8. Vasan S., Hurley A., Schlesinger S.J., Hannaman D., Gardiner D.F., Dugin D.P., et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE 2011, 6:e19252.
9. Wichmann M.W., Zellweger R., DeMaso C.M., Ayala A., Chaudry I.H. Mechanism of immunosuppression in males following trauma-hemorrhage. Critical role of testosterone. Arch Surg 1996, 131:1186-1191. discussion 91-2.
10. Mercader M., Bodner B.K., Moser M.T., Kwon P.S., Park E.S., Manecke R.G., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001, 98:14565-14570.
11. Drake C.G., Doody A.D., Mihalyo M.A., Huang C.T., Kelleher E., Ravi S., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249.
12. Lundberg K., Roos A.K., Pavlenko M., Leder C., Wehrum D., Guevara-Patino J., et al. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Vaccine 2009, 27:1557-1565.
13. Chakraborty N.G., Stevens R.L., Mehrotra S., Laska E., Taxel P., Sporn J.R., et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003, 52:497-505.
14. Forsberg O., Carlsson B., Malmstrom P.U., Ullenhag G., Totterman T.H., Essand M. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate 2009, 69:70-81.
15. Olson B.M., McNeel D.G. C.D8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother 2011, 60:781-792.
16. Hurwitz M.D., Kaur P., Nagaraja G.M., Bausero M.A., Manola J., Asea A. Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother Oncol 2010, 95:350-358.
17. Morse M.D., McNeel D.G. T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate 2012, 72:1239-1247.
18. Roden A.C., Moser M.T., Tri S.D., Mercader M., Kuntz S.M., Dong H., et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004, 173:6098-6108.
19. Morse M.D., McNeel D.G. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010, 71:496-504.
20. Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001, 167:7150-7156.
21. Sorrentino C., Musiani P., Pompa P., Cipollone G., Di Carlo E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2011, 17:1571-1581.
22. Tang S., Moore M.L., Grayson J.M., Dubey P. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012, 72:1975-1985.
23. Miller A.M., Ozenci V., Kiessling R., Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005, 28:389-395.
24. Roos A.K., Eriksson F., Walters D.C., Pisa P., King A.D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther 2009, 17:1637-1642.
25. Lladser A., Ljungberg K., Tufvesson H., Tazzari M., Roos A.K., Quest A.F., et al. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 2010, 59:81-92.
26. Roos A.K., Moreno S., Leder C., Pavlenko M., King A., Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006, 13:320-327.
27. McNeel D.G., Dunphy E.J., Davies J.G., Frye T.P., Johnson L.E., Staab M.J., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
28. Kouiavskaia D.V., Berard C.A., Datena E., Hussain A., Dawson N., Klyushnenkova E.N., et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J Immunother 2009, 32:655-666.
29. Gulley J., Chen A.P., Dahut W., Arlen P.M., Bastian A., Steinberg S.M., et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002, 53:109-117.
30. Madan R.A., Mohebtash M., Arlen P.M., Vergati M., Rauckhorst M., Steinberg S.M., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:501-508.